Fundz

Andera Partners Backs $60 Million Series C For Hypertension Medtech Sonivie

PRIVATEJan 15, 2023

Amount Raised

$60 Million

Round Type

Series C

MedicalMedical Device

Investors

Tech WaldOmega FundsSupernova InvestAndera Partners

Description

SoniVie, an Italy and Israel-run med tech seeking to treat hypertension through the use of ultrasound, has closed a $60 million series C round to make headway toward its clinical and regulatory pipeline.

Quick answer

SoniVie raised $60 Million in a Series C round, dated January 15, 2023. Investors: Tech Wald, Omega Funds, Supernova Invest and Andera Partners.

How much did SoniVie raise?
SoniVie raised $60 Million in a Series C round on January 15, 2023.
Who invested in SoniVie?
Tech Wald, Omega Funds, Supernova Invest and Andera Partners are named as investors in this round.
What does SoniVie do?
Founded in 2014 on the achievements of the Therapeutic Intra-Vascular UltraSound-based technology (TIVUS) developed by Cardiosonic for Renal Artery Denervation, Sonivie further developed the technology for Pulmonary..

Source: Fundz verified event record.

Who else raised in Medical and Medical Device around the same time

Companies in the same sectors as SoniVie that raised within 45 days of this round, from Fundz verified event records.

  • SigTuple raised $4.5M (Seed) on March 1, 2023.
  • Rhaeos raised $11M (Series A) on February 16, 2023.
  • Rhaeos raised $6.2M on February 15, 2023.
  • Ostial Corporation raised $7.5M (Series C) on February 8, 2023.
  • Otolith Labs raised $25M on January 23, 2023.
  • Julier Medical raised $3.2M (Seed) on January 23, 2023.

Who to call at SoniVie, and when

A new round usually means SoniVie is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day SoniVie raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at SoniVie, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at SoniVie. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

SoniVie

About

Founded in 2014 on the achievements of the Therapeutic Intra-Vascular UltraSound-based technology (TIVUS) developed by Cardiosonic for Renal Artery Denervation, Sonivie further developed the technology for Pulmonary Hypertension. TIVUS has been performing clinical trials in both PAH and RDN and has been awarded three Breakthrough Device Designation from the US FDA to treat PAH patients and Uncontrolled and Resistant Hypertension patients, and has obtained a Premarket Application for FDA approval for PAH.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment SoniVie raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for SoniVie's next move

See what Strategic adds

SoniVie raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.